- Home
- IGA vs RCEL Comparison
IGA vs RCEL Comparison
Compare IGA & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- RCEL
- Stock Information
- Founded
- IGA 2005
- RCEL N/A
- Country
- IGA United States
- RCEL United States
- Employees
- IGA N/A
- RCEL N/A
- Industry
- IGA Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- IGA Finance
- RCEL Health Care
- Exchange
- IGA Nasdaq
- RCEL Nasdaq
- Market Cap
- IGA 152.5M
- RCEL 161.5M
- IPO Year
- IGA N/A
- RCEL N/A
- Fundamental
- Price
- IGA $9.86
- RCEL $5.42
- Analyst Decision
- IGA
- RCEL Strong Buy
- Analyst Count
- IGA 0
- RCEL 4
- Target Price
- IGA N/A
- RCEL $16.50
- AVG Volume (30 Days)
- IGA 42.3K
- RCEL 316.4K
- Earning Date
- IGA 01-01-0001
- RCEL 08-07-2025
- Dividend Yield
- IGA 8.93%
- RCEL N/A
- EPS Growth
- IGA N/A
- RCEL N/A
- EPS
- IGA N/A
- RCEL N/A
- Revenue
- IGA N/A
- RCEL $71,661,000.00
- Revenue This Year
- IGA N/A
- RCEL $57.16
- Revenue Next Year
- IGA N/A
- RCEL $36.69
- P/E Ratio
- IGA N/A
- RCEL N/A
- Revenue Growth
- IGA N/A
- RCEL 41.35
- 52 Week Low
- IGA $7.77
- RCEL $4.71
- 52 Week High
- IGA $8.88
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- IGA 42.54
- RCEL 43.61
- Support Level
- IGA $9.87
- RCEL $5.11
- Resistance Level
- IGA $9.98
- RCEL $5.55
- Average True Range (ATR)
- IGA 0.10
- RCEL 0.31
- MACD
- IGA -0.02
- RCEL 0.10
- Stochastic Oscillator
- IGA 28.57
- RCEL 69.61
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.